11 β-hydroxysteroid dehydrogenase—why is it important for the nephrologist? by Escher, G. et al.
1506
display positive staining for the fibroblast marker
FSP-1 in late stages of fibrosis, indicating possible
transdifferentiation. Nadasdy and collegues recently
described the occurrence of interstitial cells with posi-
tivity for low-molecular-weight cytokeratin in sections
from human end-stage renal disease [13]. Interestingly
these cells were not atrophic but displayed high prolif-
erative activity. Epithelial-mesenchymal transdifferen-
tiation is known to occur during development but can
also be induced in differentiated organs such as the
thyroid [8]. Furthermore, loss of the basement mem-
brane is frequently observed in end-stage renal failure
and may facilitate the change in the state of differenti-
ation, as studies in other epithelial cell systems indicate
[8]. Thus the possibility of transdifferentiation of epi-
thelial cells into fibroblasts in the mostly mesenchym-
ally derived kidney is intriguing.
Conclusion
Renal fibroblasts are not simply undifferentiated
mesenchymal cells but have to be regarded as differen-
tiated interstitial cells. Active, matrix producing
(myo)fibroblasts are in large part derived from a
subpopulation of resident interstitial cells. In addition,
however, they are possibly generated by the trans-
differentiation of other cellular elements including
tubular epithelial cells. Nevertheless, further studies
are needed to determine if seemingly transdifferentiated
epithelial cells are in fact participating in the produc-
tion of extracellular matrix as they may do in vitro.
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Introduction
Adrenal steroids play a certain role in the genesis
of hypertension. Apart from hyperaldosteronism and
the rare adrenogenital syndrome, some novel findings
focused attention on 11 /?-hydroxysteroid dehydro-
genase (1 l/?-OHSD). Abnormal activity of this enzyme
not only accounts for some cases of congenital mineral-
ocorticoid type of hypertension, but is also involved
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in hypertension provoked by liquorice and other xeno-
biotics, and might even be implicated in hypertension
in renal failure. The following comment is intended to
give a brief summary of the current state of the art for
the non-expert in this field.
Characteristics of 11/MDHSD
11 /J-OHSD is the enzyme accounting for the conversion
of endogenous cortisol to cortisone or exogenous
prednisolone to prednisone (Figure 1). Both cortisone
and prednisone exhibit hardly any glucocorticoid
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Fig. 1. Interconversion of cortisol to cortisone by 11/J-OHSD in the
presence of NADP. The reaction is reversible. According to the
structure homology between cortisol and prednisolone (one addi-
tional double bond in the A ring), it is assumed that the same
mechanism occurs for the conversion of prednisolone to prednis-
one [38].
activity because they have negligible affinity to gluco-
corticoid receptors, whereas cortisol and prednisolone
bind to glucocorticoid receptors and are thus biologic-
ally active glucocorticoids [1,2].
For a long time there was debate on whether one
enzyme was catalysing the reaction in both directions
or whether there was one enzyme catalysing the oxida-
tion and another catalysing the reduction. In 1988,
Monder purified a protein from rat liver that catalysed
only oxidation [3]. This protein was used to find the
corresponding cDNA [4]. When this cDNA was
expressed in a toad-bladder cell line, it catalysed the
reduction only [5]. When we expressed the same cDNA
of 11^-OHSD in COS-1 cells, which are devoid of
spontaneous 11/J-OHSD activity, we found that the
cDNA was encoding for a protein that could catalyse
both reactions in the presence of appropriate cofactors
[6]. The rate of oxidation in these cell extracts was
higher than the rate of reduction [6]. In 1991 White
and co-workers found on the basis of sequence homo-
logy with rat 11/J-OHSD a human NADP-dependent
11/J-OHSD with similar biological features to that
found in rats [7].
The cDNA of llj?-OHSD cloned by Monder and
collaborators encodes for a 34-kDa NADP-depen-
dent enzyme named now 11/J-OHSD, [4, 8]. In 1991
Krozowski found a short form of 11/J-OHSD, in the
kidney which was missing the first 26 amino acids
[9,10]. The biological relevance of this fragment is
unknown since in the hands of the authors and our-
selves using the expression system of COS-1 cells, no
11/J-OHSD activity was found. In an attempt to find
a new 11/7-OHSD by expression cloning, Naray et al.
injected mRNA from kidney collecting ducts cells into
oocytes and described NAD-dependent 11 /J-OHSD
activity: the corresponding enzyme has not been
sequenced until know [11]. In 1994 Krozowski found
by means of expression cloning in CHOP-4 cells a
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protein with lljS-OHSD activity named llj?-OHSD2
[12]. For that purpose he used a human kidney cDNA
library [12]. The affinity of ll/?-OHSD2 for cortisol is
in thenM range [12], whereas that of 11^-OHSD, is
in the uM range [13]. Since cortisol and corticosterone
concentrations in mammalians are under physiological
conditions in the nanomolar and not in the micromolar
range, it appears that 11£-OHSD2 rather than lljS-
OHSDX is suitable for regulating steroids in the low
physiological concentration range.
The intracellular localization of 1 l/?-OHSD, but not
ll/?-OHSD2 has been investigated. lljS-OHSDj is
mainly located in the microsomes [14]; however, there
is also some evidence that it is present in the nuclei
[15]. 11/J-OHSD activity has been found in most tissues
[16]. The activity varies from organ to organ more
than 40-fold, as we have demonstrated in vivo by
assessing the ratios of prednisolone/prednisone in
different organs from rats [17].
ll/?-OHSD provides mineralocorticoid specificity
In-vitro studies with cloned mineralocorticoid receptors
demonstrated that the mineralocorticoid receptor
cannot distinguish between cortisol, corticosterone and
aldosterone [18]. Cortisol circulates in a 100-fold molar
excess to aldosterone in vivo. Thus cortisol rather than
aldosterone should activate mineralocorticoid recep-
tors in vivo, but this is not the case, as it is well
established that in vivo only aldosterone is a potent
mineralocorticoid hormone. Since mineralocorticoid-
specific effects of aldosterone cannot be explained by
receptor specificity, another mechanism has been pro-
posed by Funder and co-workers [18] and Edwards
and co-workers [19]. These authors hypothesized that
11 /J-OH corticosteroids such as cortisol or cortico-
sterone are inactivated locally into cortisone and dehy-
drocorticosterone by 11/J-OHSD, an enzyme which
cannot inactivate aldosterone because the 11 /?-OH
group of aldosterone is protected by a covalent hemia-
cetal bond between C n and C18 of the aldosterone
molecule. By this mechanism only aldosterone has
access to the mineralocorticoid receptor. This theory
is supported by the following findings.
First, congenital deficiency of 11 /J-OHSD causes a
mineralocorticoid type of hypertension (apparent min-
eralocorticoid exess) with low aldosterone and low
renin that can be cured by replacing the endogenous
cortisol by glucocorticoids without an 11 /?-hydroxy
group [20].
Second, the inhibition of 11/J-OHSD in vivo by
xenobiotics leads to a low renin, low aldosterone type
of hypertension. This kind of hypertension has been
observed in subjects taking carbenoxolone, an oral
antacid agent, gossypol, a male contraceptive agent
which could not be marketed due to the side effects,
glycyrrhetinic acid, the ingredient of liquorice and
possibly various other less well definied endo- and
xenobiotics [6,21-25].
Practically, the most relevant inhibitor of 110-OHSD
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is certainly glycyrrhetinic acid. This is a steroid molec-
ule that has been said in many textbooks to exhibit
mineralocorticoid activity by binding to the mineral-
ocorticoid receptor. However careful in-vitro studies
revealed that glycyrrhetinic acid has no affinity for this
receptor [26] and that glycyrrhetinic acid cannot induce
sodium retention and potassium excretion in adrenalec-
tomized mammalians. The mineralocorticoid effect
of glycyrrhetinic acid can only be restored in adrena-
lectomized animals by administering concomitantly
glycyrrhetinic acid with exogenous cortisol. The mech-
anism proposed for this observation is the inhibition
of 1l/?-OHSD by glycyrrhetinic acid which gives access
of cortisol to the mineralocorticoid receptor. Thus in
the presence of an inhibited 1l/?-OHSD, cortisol func-
tions as a mineralocorticoid hormone.
In order to protect the mineralocorticoid receptor
from promiscuous cortisol, ll/?-OHSD has to fulfil
some biochemical and anatomical prerequisits. First it
has to have a high affinity for cortisol and corticos-
terone in the nanomolar range, second it has to favour
the oxidation over the reduction, and third it has to
colocalize with the mineralocorticoid receptors. These
prerequisits match best, although not completely, with
ll/?-OHSD2[12].
1 l/?-OHSD protects the fetus from high cortisol
levels
Another biological relevance of ll/?-OHSD is its role
in protecting the fetus from maternal glucocorticoids.
Most maternal cortisol crossing the human placenta is
converted to cortisone [27]. By that mechanism, the
fetus is protected from the growth-retarding effects of
maternal gluocorticoids, which circlulate at concentra-
tions 5-10 times higher than those in the fetus [28].
Benediktsson et al. [29] proposed that glucocorticoid
exposure in utero might be a predisposing factor for
hypertension in the future adult life of the fetus.
Epidemiological evidence revealed that hypertension
is strongly predicted by the combination of low
birthweight and large placenta in humans [30]. It was
hypothesized that this association could be due to
increased fetal exposure to maternal glucocorticoids.
In rats placental ll/?-OHSD activity was found to
correlate positively with term fetal weight and nega-
tively with placental weight. Rats treated during preg-
nancy with dexamethasone had offspring with lower
birthweight and higher blood pressure than untreated
rats [29]. Thus increased fetal glucocorticoid exposure
secondary to attenuated placental ll/?-OHSD activity
might link low birthweight and high placental weight
with hypertension. As a corollary, inhibition of 11/?-
OHSD in pregnant women might be hazardous, a
hypothesis in line with the fact that many authorities
discourage the use of frusemide—an inhibitor of 11/?-
OHSD—during pregnancy [6].
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11^-OHSD alleviates glucocorticoid-mediated
inhibition of testosterone synthesis in Leydig cells
Long-term exposure to elevated levels of circulating
glucocorticoids in stress, Cushing's disease, or during
immunosuppressive therapy lead to depressed plasma
testosterone [31,32]. Leydig cells from adult rats
exhibit a high activity of ll/?-OHSD [33]. In-vitro
studies using Leydig cells revealed that the inhibition
of testosterone secretion by ll/?-OHSD glucocortico-
steroids was enhanced by the inhibition of 1 l/?-OHSD.
From these studies it was concluded that ll/?-OHSD
protects the Leydig cells from endogenous glucocort-
icoids [34,35]. This protection is absent in newborn
rats. The developmental rise in intracellular 1 l/?-OHSD
in Leydig cells occurs in parallel with the increased
capability of the Leydig cells to produce testosterone,
suggesting that the absence of 1 l/?-OHSD protects the
organism in the early stage of life from unwarranted
testosterone [35].
11/f-OHSD protects glucocorticoid receptors from
ll/?-hydroxy glucocorticosteroids
The presence of a hydroxyl group at position 11 of
the molecule is a prerequisite for steroid binding to
the glucocorticoid receptors. Therefore cortisol and
prednisolone bind to glucocorticoid receptors and are
thus biologically active glucocorticoids, whereas cortis-
one and prednisone exhibit hardly any glucocorticoid
activity (Figure 1). Local inactivation of ll/?-hydroxy
steroids into 11-keto steroids by ll/?-OHSD might
therefore modulate glucocorticoid access to the recep-
tors. Such an effect has been shown in cell culture
experiments and in vivo in humans.
Rat pituitary tumour GH3 cell lines express several
glucocorticoid target genes, including prolactin. The
potency of 11 /?-hydroxysteroids to inhibit the release
of prolactin is enhanced by the addition in vitro of
glycyrrhetinic acid [36], an inhibitor of ll/?-OHSD.
Furthermore, in vivo glycyrrhetinic acid potentiates the
vasoconstrictor effect of cortisol but not that of dexa-
methasone, a steroid which is not an appropriate
substrate for 11/J-OHSD [37]. Thus 1 l/?-OHSD modu-
lates access of glucocorticoids to glucocorticoid recep-
tors. Variable activity of 11/J-OHSD may therefore at
least partly explain intra- and interindividual differ-
ences in the expression of glucococorticoid effects in
clinical practice.
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